Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising from Immune Checkpoint Inhibitors
Miscellaneous
Miscellaneous
This phase II trial tests how well itacitinib works in in patients with immune related adverse events (irAEs) arising from immune checkpoint inhibitors (ICI) that do not respond to steroids (steroid refractory). Steroids are the usual treatment for these side effects. However, sometimes steroids do not improve or fix the side effects. Giving itacitinib may be effective in treating patients with known or suspected problems coming from ICIs, that do not resolve or improve with steroids, by reducing the patient's immune system response that can cause the irAEs.
Miscellaneous
II
Johnson, Douglas
NCT05660421
VICCCTT2193
Rigosertib Plus Pembrolizumab in Treating Patients with Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Melanoma
Melanoma
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic), and that has not responded to previous treatment with PD-1 or PD-L1 inhibitors (refractory). Rigosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may change the immune system to make immunotherapy more effective. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rigosertib in combination with pembrolizumab may be more effective in treating patients with unresectable metastatic melanoma that has not responded to previous treatment with PD-1 or PD-L1 inhibitors than giving either drug alone.
Melanoma
II
Johnson, Douglas
NCT05764395
VICCMEL2218
LESS VT- Flexibility Sensor Enabled Substrate Targeted Ablation for teh Reduction of VT (LESS VT) Study
Not Available
II
Tandri, Harikrishna
CRE-ARR0016
VANISH 2- Ventricular Tachycardia Antiarrhythmics or Ablation in Structural Heart Disease 2
Not Available
III
Kanagasundram, Arvindh
CRE-CHF0001
SOS-AMI - Protocol ID-07-076A301 Selatogrel Outcome Study in suspected Acute Myocardial Infarction (SOS-AMI)
Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction
Not Available
III
Defilippis, Andrew
CRE-GEN0002
APOLLO-B Expanded Access Protocol ALN-TTR02-014 Expanded Access Protocol to Provide Patisiran to Patients with Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) with Cardiomyopathy
Not Available
II/III
Hung, Rebecca
CRE-CHF0009
REDUCE LAP II- A study to evaluate the Corvia Medical Inc IASD system II REDUCE Elevated Left Atrial Pressure in Patients with Hear Failure
Not Available
II
Gupta, Deepak
CRE-CHF0002
ALL-IN - Targeting Inflammation and Alloimmunity in Heart Transplant Recipients with Tocilizumab
Not Available
Schlendorf, Kelly
CRE-CHF0005